Catherine McGrath Updated May 28, 2025 at 11:53 AM GameStop announced a shift to Bitcoin investing in March. (Michael M. Santiago—Getty Images) GameStop, the
Uncategorized
The most bizarre side effects of GLP-1 weight loss drugs, from ‘Ozempic feet’ to cavities to a runny nose
Americans are jumping for jabs. Surveys show at least one in eight US adults have given GLP-1 drugs like Ozempic and Wegovy a shot,
Top 5 SEC Enforcement Developments for April 2025
Each month, we publish a roundup of the most important SEC enforcement developments for busy in-house lawyers and compliance professionals. For the month when
SEC revokes license, registration of online lending firm Digido
MANILA, Philippines – The Securities and Exchange Commission (SEC) revoked the corporate registration and license of online lending company Digido for operating unlicensed branches.
GLP-1 prescriptions for weight loss are shooting up, despite obstacles
This audio is auto-generated. Please let us know if you have feedback. Dive Brief: More adults are taking GLP-1 drugs to control their weight,
23andMe to voluntarily delist from Nasdaq, deregister with SEC
23andMe announced Tuesday it will voluntarily delist from the Nasdaq and deregister with the U.S. Securities and Exchange Commission after filing for Chapter 11
No Eating After 8 PM. Does It Actually Help You Lose Weight?
No Eating After 8 PM. Does It Actually Help You Lose Weight? (Credits: Pexels) We’ve all heard it at least once in our lives,
Losing weight – back to basics
Published Wed, May 28, 2025 · 05:57 PM DIETERS around the world dreaming of a quick-fix remedy that melts away kilos without any effort,
Can Popular Weight-Loss Drugs Protect Against Obesity-Related Cancers?
New data suggest that glucagon-like peptide 1 (GLP-1) receptor agonists, used to treat diabetes and obesity, may also help guard against obesity-related cancers. In
The oral alternative to popular weight loss injection
The landscape of weight management and diabetes treatment stands at the cusp of significant transformation with the development of orforglipron, an oral medication demonstrating